TPST vs VRTX · $26.3M cap vs P/E 30, rev $12.00B
Tempest Therapeutics Inc (TPST) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Tempest Therapeutics Inc (TPST) is a biotechnology company listed on US.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
TPST does not have a complete income-statement cache yet.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
TPST currently screens at market cap $26.3M. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the TPST and VRTX stock pages for the full models.
Not investment advice.